Prostate device gets European approval

Israeli biotech Butterfly Medical has received the CE Mark for its novel medical device for non-surgical treatment of Benign Prostate Hyperplasia (BPH) or enlarged prostate that affects 105 million men globally. The device is inserted in a 10-minute procedure under local anesthetic.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published.